Skip to main content
See every side of every news story
Published • loading... • Updated

US Exempts Select Indian Speciality Drugs From 100% Tariff as Wider Pharma Levy Kicks In

The exemptions cover rare-disease, infertility and gene-therapy drugs as the US implements Trump’s Section 232 pharmaceutical tariff plan.

  • The US Commerce Department published a notice in the Federal Register stating that India and 19 other countries are exempt from ad valorem tariffs on specialty drugs and related ingredients.
  • President Donald Trump issued a proclamation imposing a 100 per cent tariff on patented pharmaceutical imports under Section 232 of the Trade Expansion Act to encourage domestic production.
  • Eligible products for the zero-tariff rate include drugs designated for rare diseases, infertility treatments, gene therapies, and antibody-drug conjugates, or ADCs; components also qualify for exemption.
  • While the exemption took effect on July 31 for some companies, it applies to other covered entities starting today, and generic pharmaceutical products remain exempt from Section 232 tariffs.
  • Qualifying products from these jurisdictions receive zero per cent tariffs because they maintain a current or forthcoming trade and security framework agreement with the US; "pharmaceutical articles" encompass finished products and key starting materials.
Insights by Ground AI

31 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 55% of the sources lean Right
55% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Social News XYZ broke the news on Monday, September 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal